Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
Phase 3
Active, not recruiting
- Conditions
- Endocrine System DiseasesParathyroid DiseasesChronic Hypoparathyroidism
- Interventions
- Combination Product: eneboparatideCombination Product: Placebo
- First Posted Date
- 2023-03-21
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Amolyt Pharma
- Target Recruit Count
- 165
- Registration Number
- NCT05778071
- Locations
- π―π΅
Osaka City Hospital, Osaka, Japan
πΊπΈNorthern Nevada Endocrinology, Reno, Nevada, United States
π¨π¦Bone Research and Education Center, Oakville, Ontario, Canada
AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Amolyt Pharma
- Target Recruit Count
- 132
- Registration Number
- NCT05239221
- Locations
- π³π±
PRA-EDS, Groningen, Netherlands
ππΊAmolyt Pharma Investigational Site Hungary, Budapest, Hungary
Β© Copyright 2025. All Rights Reserved by MedPath